

In the specification.


The specification is amended to correctly recite the priority of this application. No new matter is added by this Amendment.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (415) 217-6022.

EXPRESS MAIL LABEL NO:

EL7079148/7US

Respectfully submitted,



Peter K. Seperack
Attorney for Applicant(s)
Reg. No. P-47,932

STEVEN MORRIS
MACPHERSON

100 W. 10TH ST.
SUITE 100
DENVER, CO 80202
TEL: (303) 455-1100
FAX: (303) 455-1100

APPENDIX I

CLAIMS PENDING AS OF DECEMBER 4, 2000

- b) contacting the second cell with the test compound, and

c) detecting the expression of the second reporter gene.

9. (Amended) A method of claim 8, wherein the response element is from the *Xenopus vitellogenin A2* gene.

10. (Amended) A method of claim 1, wherein the cell further comprises a promoter comprising a standard estrogen response element which regulates expression of second reporter gene.

11. (Amended) A method of claim 10, wherein the response element is from the *Xenopus vitellogenin A2* gene.

12. (Amended) An estrogen agonist identified by the method of claim 1.

13. A method for screening a test compound for the ability to inhibit transcription through an indirect estrogen response, the method comprising:

a) providing a cell comprising an estrogen receptor and a promoter comprising an API site which regulates expression of a reporter gene;

b) contacting the cell with the test compound and a compound known to mediate an indirect estrogen response;

c) detecting the expression of the reporter gene.

14. (Amended) The method of claim 13, wherein the compound is known to mediate an indirect estrogen response is tamoxifen.

15. (Amended) A method of claim 13, wherein the cell over-expresses the estrogen receptor.

16. (Amended) The method of claim 13, wherein the promoter is genetically engineered to comprise an API site

Amended: A compound identified by the method of claim 13.

18. A method for screening a test environmental compound for estrogenic activity, the method comprising:

JOHN MORRIS
ATTORNEY

1000 N. 17TH ST.
SUITE 100
DENVER, CO 80202
TEL: 303.733.1111
FAX: 303.733.1112

a) providing a cell comprising an estrogen receptor and a promoter comprising an estrogen response element which regulates the expression of a reporter gene;

b) contacting the cell with the test compound; and

c) detecting the expression of the reporter gene.

19. (Amended) The method of claim 18, wherein the cell further comprises a promoter comprising an AP1 site which regulates expression of a second reporter gene.

20. (Amended) The method of claim 18, wherein the reporter gene is CAT.

21. (Amended) The method of claim 18, wherein the cell over-expresses the estrogen receptor.

22. (Amended) The method of claim 18, wherein the cell is an ERC1 cell.

23. A method of inhibiting agonistic activity of an antiestrogen compound, said method comprising administering with said antiestrogen compound an inhibitor selected from the group consisting of genistein, staurosporine, 6-thioguanine, and 2 aminopurine.

24. (Amended) The method of claim 23, wherein said inhibiting agonistic activity comprises inhibiting an indirect estrogen response.

25. (Amended) The method of claim 23, wherein said antiestrogen compound is tamoxifen.

26. (Amended) The method of claim 23, wherein said inhibition is *in vivo*.

JOSEPH M. MORRIS
BY PETERSON

11/11/95
11/11/95
11/11/95
11/11/95